Literature DB >> 7462697

Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers.

A J Mortiz, C Kunz, H Hofman, E Liehl, P Reeve, H F Maassab.   

Abstract

A cold-recombinant influenza A virus, CR 22, derived from A/Ann Arbor/6/60 (H2N2) cold-adapted virus and A/Victoria/3/75 (H3N2) wild-type virus, was tested in adult volunteers. CR 22 induced only low-grade clinical reactions in volunteers who had low titers of serum antibodies. Virus could be reisolated from about one-third of the volunteers, but only at low titers. No revertant viruses were found, and there was no evidence for transmission of virus to unvaccinated volunteers housed in the close contact with the vaccinees. A high proportion of the volunteers seroconverted, and the mean titers of serum antibody after immunization suggest that a high degree of protection is induced by vaccination with liver CR 22 virus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7462697     DOI: 10.1093/infdis/142.6.857

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Biological characteristics of a cold-adapted influenza A virus mutation residing on a polymerase gene.

Authors:  T Odagiri; A Tosaka; N Ishida; H F Maassab
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

Review 2.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

3.  Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens.

Authors:  G A Tannock; J A Paul; R D Barry
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

4.  Epidemic influenza in Greater London.

Authors:  C C Spicer; C J Lawrence
Journal:  J Hyg (Lond)       Date:  1984-08

5.  Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers.

Authors:  N Yamane; Y Nakamura; M Yuki; T Odagiri; N Ishida
Journal:  J Hyg (Lond)       Date:  1984-04

6.  Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.

Authors:  M L Clements; S O'Donnell; M M Levine; R M Chanock; B R Murphy
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

7.  Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees.

Authors:  G I Alexandrova; F I Polezhaev; G N Budilovsky; L M Garmashova; N A Topuria; A Y Egorov; Y R Romejko-Gurko; T A Koval; K V Lisovskaya; A I Klimov
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

8.  Infant rat model of attenuation for recombinant influenza viruses prepared from cold-adapted attenuated A/Ann Arbor/6/60.

Authors:  M Ali; H F Maassab; R Jennings; C W Potter
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

9.  Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge.

Authors:  T R Cate; R B Couch
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.